Brief: Oxigene announces positive initial data from phase 1b study of CA4P in combination with pazopanib
05/11/2015 21:15
Nov 5 (Reuters) - OXiGENE Inc OXGN.O : * Press release - Oxigene announces positive initial data from phase 1b study of ca4p in combination with pazopanib in patients with advanced recurrent ovarian cancer * Says expect to move into the phase 2 portion of the study in early 2016 * Says plans to focus on initiation of two late-stage clinical programs for ca4p in 2016 * Source text for Eikon urn:newsml:reuters.com:*:nGNXVETVFa * Further company coverage OXGN.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas